Katherine Beck1,2,3, Robert McCutcheon1,2,3, Lucy Stephenson2, Marcela Schilderman2, Natasha Patel2, Rosalind Ramsay2, Oliver D Howes1,2,3. 1. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, UK. 2. South London and the Maudsley NHS Foundation Trust, London, UK. 3. MRC London Institute of Medical Sciences, Hammersmith Hospital Campus, London, UK.
Abstract
BACKGROUND: Treatment-resistant schizophrenia (TRS) is a major cause of disability. Clozapine is currently the only antipsychotic medication licensed for its treatment. However, the rate of treatment resistance among outpatients with schizophrenia or other psychoses, and the rate of use of clozapine among them, is not known. AIMS: The aims of this study are (a) to determine the point prevalence of treatment-resistant psychosis in a community sample, and (b) to determine the number of patients with TRS who have never had a clozapine trial. METHOD: Clinico-demographic data were extracted from the case notes for 202 patients from two community mental-health teams. RESULTS: We found that 56% (99/176) had a diagnosis of TRS, and 52% (51/99) of these patients had never been treated with clozapine. Patients of non-white ethnicity were less likely to have had a clozapine trial (p=0.009). The point prevalence of treatment resistance within the bipolar affective disorder sample was 19% (5/26). CONCLUSION: These findings suggest that TRS is common in the community mental-health team, and a large proportion of these patients have not received clozapine. These findings indicate that identifying and treating treatment resistance should be a focus of community services for schizophrenia.
BACKGROUND: Treatment-resistant schizophrenia (TRS) is a major cause of disability. Clozapine is currently the only antipsychotic medication licensed for its treatment. However, the rate of treatment resistance among outpatients with schizophrenia or other psychoses, and the rate of use of clozapine among them, is not known. AIMS: The aims of this study are (a) to determine the point prevalence of treatment-resistant psychosis in a community sample, and (b) to determine the number of patients with TRS who have never had a clozapine trial. METHOD: Clinico-demographic data were extracted from the case notes for 202 patients from two community mental-health teams. RESULTS: We found that 56% (99/176) had a diagnosis of TRS, and 52% (51/99) of these patients had never been treated with clozapine. Patients of non-white ethnicity were less likely to have had a clozapine trial (p=0.009). The point prevalence of treatment resistance within the bipolar affective disorder sample was 19% (5/26). CONCLUSION: These findings suggest that TRS is common in the community mental-health team, and a large proportion of these patients have not received clozapine. These findings indicate that identifying and treating treatment resistance should be a focus of community services for schizophrenia.
Authors: C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes Journal: CNS Drugs Date: 2022-06-27 Impact factor: 6.497
Authors: Daniela Fonseca de Freitas; India Patel; Giouliana Kadra-Scalzo; Megan Pritchard; Hitesh Shetty; Matthew Broadbent; Rashmi Patel; Johnny Downs; Aviv Segev; Mizanur Khondoker; James H MacCabe; Kamaldeep Bhui; Richard D Hayes Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2022-03-04 Impact factor: 4.519
Authors: Karen S Ambrosen; Martin W Skjerbæk; Jonathan Foldager; Martin C Axelsen; Nikolaj Bak; Lars Arvastson; Søren R Christensen; Louise B Johansen; Jayachandra M Raghava; Bob Oranje; Egill Rostrup; Mette Ø Nielsen; Merete Osler; Birgitte Fagerlund; Christos Pantelis; Bruce J Kinon; Birte Y Glenthøj; Lars K Hansen; Bjørn H Ebdrup Journal: Transl Psychiatry Date: 2020-08-10 Impact factor: 6.222
Authors: Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio Journal: Neuropsychiatr Dis Treat Date: 2021-07-01 Impact factor: 2.570